Back to Information Overview
TOKYO (September 28, 2015) – Amgen Astellas BioPharma K.K. (Headquarters: Tokyo, General Manager and Representative Director: Eiichi Takahashi) announces that it aims to form an organization to efficiently provide information and profound knowledge on products and diseases to the medical community, to deliver the value of our innovative medicines to eligible patients. It recently established the new East Japan Region, Central Japan Region, and West Japan Region in the Sales & Marketing, and will begin preparation to establish a sales organization.
To establish this organization, the following three employees of Astellas Pharma Inc. will join Amgen Astellas BioPharma K.K. on October 1.
October 1, 2015 Please note current position in brackets
Tetsuro Kunigo Head of East Japan Region, Sales & Marketing (General Manager, Tohoku Branch, Sales & Marketing, Astellas Pharma Inc.)
Kazuo Terasoma Head of Central Japan Region, Sales & Marketing (General Manager, Nagoya Branch, Sales & Marketing, Astellas Pharma Inc.)
Katsuharu Kohno Head of West Japan Region, Sales & Marketing (Executive Director, Planning & Administration, Nagoya Branch, Sales & Marketing, Astellas Pharma Inc.)
About Amgen Astellas BioPharma
Amgen Astellas BioPharma K.K. is a Japanese company that began operations on October 1, 2013, to provide breakthrough-science-based medicines to help address unmet medical needs of patients in Japan. The company is a joint venture between Amgen, the world’s largest independent biotechnology company, and Astellas Pharma Inc., a leading R&D-oriented global pharmaceutical company. Amgen Astellas BioPharma leverages the capabilities of both companies – Amgen’s science and pipeline candidates coupled with Astellas’ deep knowledge of Japanese patient and physician needs, long-term commercial and regulatory experience, and strong presence as a leading company in Japan – to contribute to the creation of a healthy society.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us onwww.twitter.com/amgen.
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.
Amgen Astellas BioPharma K.K.
Value, Access and Policy (Tel: +81-3-5293-9870/ FAX: +81-3-5293-9897)